Becton, Dickinson and Company (BDX) Q4 2022 Earnings Call Transcript

Becton, Dickinson and Company (NYSE:BDX) Q4 2022 Earnings Conference Call November 10, 2022 8:00 AM ET

Company Participants

Francesca DeMartino - SVP & Head, IR

Thomas Polen - President, CEO & Chairman

Christopher DelOrefice - EVP & CFO

Mike Garrison - President of the Medical Segment

Dave Hickey - President of Life Sciences Segment

Rick Byrd - President of Interventional Segment

Conference Call Participants

Lawrence Biegelsen - Wells Fargo

Vijay Kumar - Evercore ISI

Robert Marcus - JPMorgan

Matthew Taylor - Jefferies

Josh Jennings - Cowen and Company

Frederick Wise - Stifel

Operator

Hello, and welcome to BD's Earnings Call for the Fourth Quarter and Full Year Fiscal 2022. At the request of BD, today's call is being recorded and will be available for replay through November 17, 2022 on BD's Investor Relations website on bd.com or via phone at 866-342-8591 for domestic calls, and area code +1 (203) 518-9713 for international calls. The replay bridges are now dedicated so you no longer need a conference ID to hear the replay. For today’s call, all parties have been placed in a listen-only mode until the question-and-answer session.

I will now turn the call over to BD.

Francesca DeMartino

Good morning, and welcome to BD's earnings call. I'm Francesca DeMartino, Senior Vice President and Head of Investor Relations. On behalf of the BD team, thank you for joining us. This call is being made available via audio webcast at bd.com.

Earlier this morning, BD released its results for the fourth quarter and full year of fiscal 2022. We also posted an earnings presentation that provides additional details on our performance. The press release and presentation can be accessed on the IR website at investors.bd.com.

Leading today's call are Tom Polen, BD's Chairman, Chief Executive Officer and President; and Chris DelOrefice, Executive Vice President and Chief Financial Officer. Tom will provide highlights of our performance and the continued execution of our BD 2025 strategy. Chris will then provide additional details on our FY '22 financial performance and our guidance for fiscal 2023. Following the prepared remarks, Tom and Chris will be joined for Q&A by our segment presidents, Mike Garrison, President of the Medical segment; Dave Hickey, President of the Life Sciences segment; and Rick Byrd, President of the Interventional segment.

Before we get started, I want to remind you that we will be making forward-looking statements. I encourage you to read the disclaimer in our earnings release and the disclosures in our SEC filings, which are both available on the IR website. Unless otherwise specified, all comparisons will be on a year-over-year basis versus the relevant period. Revenue percentage changes are on an FX-neutral basis unless otherwise noted.